Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression
Vivek Subbiah shared on LinkedIn:
“Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression
Authors: Madhav Channavazzala, Kapil Mayawala, Dinesh P. De Alwis, Eric Rubin, Alexandra Snyder, Jedd D. Wolchok, Antoni Ribas
While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified.
Interesting study published in Cancer cell shows that
Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023